Ananda Basu is an Endocrinology/Metabolic physician affiliated with St. Vincent's Birmingham. OpenAlex indexes 67 publications with 1,670 citations (h-index 20); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2000 6th Ave S
Birmingham, AL 352332110
Telephone
205-934-9999Provider last certified this registry record 27 Sept 2023.
Clinical trials
- SGLT2 Inhibitor Adjunctive Therapy to Closed Loop Control in Type 1 Diabetes Mellitus
Sponsor: Ananda Basu, MD
- At Home Study of a Zone-Model Predictive Control (MPC) Controller and a Health Monitoring System (HMS) With the Diabetes Assistant (DiAs) System and Run-to-Run Adaptation
Sponsor: Sansum Diabetes Research Institute
- Early Feasibility Study of Zone-MPC and HMS With DiAs in the Outpatient Setting
Sponsor: Sansum Diabetes Research Institute
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
9 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Medtronic, Inc.Program year20252 payments
- Novo Nordisk IncProgram year20252 payments
- Madrigal PharmaceuticalsProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
88.1%GLP-1 receptor agonist45.9%Ozempic53%Mounjaro47%Part D≥16 patientsInsulin Analog25.7%Tresiba Flextouch U-10028%Lantus Solostar26%Humalog Kwikpen U-10023%Novolog Flexpen23%Part D<11 patients+ 2 more classes in this area
Nervous system
6.7%Gabapentinoids6.7%Pregabalin100%Part D<11 patientsCardiovascular
5.2%Statin5.2%Atorvastatin Calcium100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2021–2026 per NIH RePORTER. The latest:
- Integrated Approaches to Close the Loop in Type 1 Diabetes
University of Alabama at Birmingham
FY2021$318,369R01DK085516
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Role of Hepatic Glycogen on Nocturnal Gluconeogenesis in Type 2 Diabetes Mellitus
The Journal of Clinical Endocrinology & Metabolism
2025 - Hyperglycemia Suppresses Lactate Clearance During Exercise in Type 1 Diabetes
The Journal of Clinical Endocrinology & Metabolism
2024
Similar KOLs
Other experts from the same institution or the same specialty.
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”